BURLINGTON, ON, June 6, 2019 /CNW/ - Rapid Dose Therapeutics Corp. ("RDT" or the "Company") (CSE: DOSE), a Canadian leader in drug delivery solutions, is pleased to announce that Dr. Rina Carlini has been appointed Vice President, Research & Innovation.
Dr. Carlini is an accomplished scientist and management executive with 25 years of experience in technology innovation, product development, commercialization within the sectors of health technology, life science, IoT, artificial intelligence, advanced manufacturing, and nanotechnology.
Dr. Carlini holds a Ph.D. in Chemistry from the University of Waterloo, and in 2017 she was awarded the Faculty of Science Alumni of Honour. She also holds several certificates from MIT, Harvard University, McMaster University in the areas of Artificial Intelligence for Business Strategy and Business Model Innovation.
Rina's professional experience spans diverse industries and leadership roles, including pharma drug discovery R&D (Merck, Syntex), as Director of Nanotechnology for Xerox Innovation Group (Canada), Director of Commercialization at GreenCentre Canada, and President & CEO of Haltech Regional Innovation Centre. In addition, Rina is the inventor of over 100 US patents; co-author of 20+ peer-reviewed research articles; serves on the board for Waterloo Institute for Nanotechnology, Concordia University's Gina Cody School of Engineering, and as an expert reviewer for several Canadian funding agencies (OCE, NSERC, CFI).
"We are excited to have Rina join the RDT team and we look forward to engaging her wealth of expertise as RDT enters the next advancement of our global growth within the drug delivery technology sector," stated Mark Upsdell, President and CEO.
"I am pleased to join RDT at this time of RDT's scaleup and growth. It is an exciting time to lead science and innovation in the life science industry," said Rina Carlini.
About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT's QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT's service based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.
For more information, visit: www.rapid-dose.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Rapid Dose Therapeutics Corp.
For further information: For inquiries please contact: Mark Upsdell, CEO, Rapid Dose Therapeutics, [email protected], Office (416) 477-1052; Ali Mahdavi, Managing Director, Spinnaker Capital Markets Inc., [email protected], Office (416) 962-3300